EMA Application withdrawn: Xegafri — Clovis Oncology UK Ltd

View source ↗

Summary

The EMA withdrew the Xegafri application from Clovis Oncology UK Ltd for non-small cell lung carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Xegafri

Snippet

Status: Application withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Clovis Oncology UK Ltd. Decision date: 27/05/2016. Orphan medicine